[ET Net News Agency, 21 December 2023] Morgan Stanley lowered its target price for
Hepalink (09989) to HKD4.5 from HKD4.7 and maintained its "equal-weight" rating.
The research house said following 3Q23 results and recent export trends, it cuts
earnings estimates for 2023-2030 by 5-10% on lower export sales and gross margins. (RC)